5 completed, 1 active not recruiting, 1 withdrawn. 7 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Iohexol: new trials by email Literature Review of Iohexol trials Research Report on Iohexol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy oral iohexol, Lymphangiography and Embolization - Chylous Ascites, Abdominal Neoplasm | Phase 2 | Completed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 42 | 2025-02-15 | 2026-03-06 |
| Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography CE-Iohexol, Iohexol - Contrast-induced Nephropathy | Phase 2 | Withdrawn | Ligand Pharmaceuticals | 2022-01-01 | 2022-04-11 | |
| Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL - Diabetes Mellitus, Type 1, Nephropathy | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 50 | 2018-10-01 | 2022-04-20 |
| Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Renal Biopsy - Type 2 Diabetes Mellitus, Obesity | Phase 1 / Phase 2 | Active not recruiting | University of Colorado, Denver | 100 | 2018-10-01 | 2023-08-15 |
| Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL, Vertical Sleeve Gastrectomy - Type 2 Diabetes Mellitus, Obesity | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 24 | 2018-10-01 | 2026-01-12 |
| Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types MB-102-- single dose of 4 µmol/kg, MB-102-- single dose of 130 mg, MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart - Acute Kidney Injury | Phase 2 | Completed | MediBeacon | 234 | 2016-05-11 | 2023-10-26 |
| Evaluation of Computer-assisted, Non-cathartic CT Colonography non-cathartic CTC - Colonic Polyps | Phase 2 / Phase 3 | Completed | Massachusetts General Hospital | 605 | 2005-06-01 | 2015-08-05 |
Kidney Diseases (3) · Diabetes Complications (2) · Diabetes Mellitus, Type 2 (2) · Diabetic Nephropathies (2) · Obesity (2) · Pediatric Obesity (2) · Abdominal Neoplasms (1) · Acute Kidney Injury (1) · Chylous Ascites (1) · Colonic Neoplasms (1) · Colonic Polyps (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Pelvic Neoplasms (1) · Weight Loss (1)
University of Colorado, Denver (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Ligand Pharmaceuticals (1) · Massachusetts General Hospital (1) · MediBeacon (1)
United States (5) · China (1)
Petter Bjornstad, MD (3) · Keith Marschke, PhD (1) · Michael Zalis, MD (1) · Richard B Dorshow, PhD (1)
PMID 32737116, PMID 35507146, PMID 22586008, PMID 36623423, PMID 39918882, PMID 41708511